Skip to main content
. 2016 Mar 21;34(20):2359–2365. doi: 10.1200/JCO.2015.63.1960

Table 1.

Clinical Characteristics of the 21-Gene RS Population (n = 109)

No. (%)
Median age at diagnosis, years (range) 52 (21-79)
Median primary tumor size, cm (range) 3.1 (0.7-15.0)
Clinical node status
 N1/2 77 (71)
 N0 18 (16)
 Unknown 14 (13)
ECOG status
 0 58 (53)
 1 46 (42)
 > 1 5 (5)
Tumor subtype
 HR positive/HER2 negative 72 (66)
 HR positive/HER2 positive 20 (18)
 HR negative/HER2 positive 10 (9)
 Triple negative 7 (6)
Site of metastasis at first diagnosis
 Bone only 50 (46)
 Visceral only 26 (24)
 Both (bone and visceral) 25 (23)
 Other* 8 (7)
No. of metastatic sites at first diagnosis
 Single organ 65 (60)
 > 1 organ 44 (40)
First systemic treatment
 Chemotherapy 26 (24)
 Endocrine therapy 52 (48)
 Chemotherapy and endocrine therapy 3 (3)
 Chemotherapy plus trastuzumab 20 (18)
 Endocrine therapy plus trastuzumab 6 (6)
RS distribution
 Low (< 18) 22 (20)
 Intermediate (18-30) 29 (27)
 High (≥ 31) 50 (46)
 Not available 8 (7)

Abbreviations: ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; RS, Recurrence Score.

*

Includes skin, pleura, contralateral axillary lymph nodes, mediastinal lymph nodes, paratracheal lymph nodes, endobronchial lymph nodes, hilar lymph nodes, and prepectoral lymph nodes.